Aclarion, Inc. (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain, published a shareholder letter from CEO Brent Ness. The letter provides an update on the company’s recent momentum and value-creating priorities for 2026, highlighting progress in expanding adoption of its Nociscan platform, growing clinical evidence, and advancing reimbursement initiatives in both the United Kingdom and the United States.
Key catalysts outlined for 2026 include pursuing reimbursement coverage from one or more regional insurance providers in the United States, which is seen as an important step toward broader payer adoption. Additionally, the company expects an initial readout from its CLARITY clinical trial in the fourth quarter of 2026. Aclarion also emphasized its strong balance sheet, with a cash runway extending into 2028, supporting continued execution on its strategic priorities.
“Our focus in 2026 remains disciplined execution against the key catalysts that we believe can expand adoption of Nociscan and strengthen the clinical and reimbursement foundation of our business,” said Brent Ness, Chief Executive Officer of Aclarion. “With increasing physician engagement, growing clinical evidence, and continued progress with payers, we believe Aclarion is well positioned to advance our mission of building a scalable technology platform for chronic low back pain while creating long-term value for patients and shareholders.”
The full CEO Shareholder Letter is available on the company’s website. For more news from Aclarion, visit the Latest News page. To find a Nociscan center, view the site map here.
Aclarion is a healthcare technology company that uses Magnetic Resonance Spectroscopy (MRS), proprietary signal processing techniques, biomarkers, and augmented intelligence algorithms to optimize clinical treatments. The company is first addressing the chronic low back pain market with Nociscan, the first evidence-supported, SaaS platform to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine. Through a cloud connection, Nociscan receives MRS data from an MRI machine for each lumbar disc being evaluated. In the cloud, proprietary signal processing techniques extract and quantify chemical biomarkers associated with disc pain. Biomarker data is entered into proprietary algorithms to indicate if a disc may be a source of pain. When used with other diagnostic tools, Nociscan provides critical insights into the location of a patient’s low back pain, giving physicians clarity to optimize treatment strategies.
The latest news and updates relating to $ACON are available in the company’s newsroom at https://tinyurl.com/aconnewsroom.
